Photo from wikipedia
ABSTRACT α-Emitter 225Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225Ac. We present… Click to show full abstract
ABSTRACT α-Emitter 225Ac has been considered a candidate for targeted α-therapy. DOTA-IBA is new a precursor targeting bone metastasis. It can be used for radionuclide labeling with 225Ac. We present a case with refractory bone pain for bone metastasis, who demonstrated an excellent therapy response after 1 cycle of 225Ac-DOTA-IBA therapy. Moreover, the patient did not have any observable adverse effects.
Keywords:
bone;
225ac dota;
case;
new radiopharmaceutical;
dota iba
Journal Title: Clinical nuclear medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical nuclear medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!